Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication.
The effects of ketanserin, a serotonin antagonist, were studied in 37 patients with intermittent claudication in a double-blind placebo-controlled, trial done in London and Leuven. 40 mg ketanserin taken orally three times a day for 4 months was associated with a clear-cut inhibition of serotonin-induced platelet aggregation but no changes were observed in pain-free and maximum walking distance on a treadmill, in ankle/arm Doppler systolic blood pressure ratio, or in reactive hyperaemia after 3 min of ischaemia. In contrast, the placebo group had increases in both pain-free and maximum walking distance (p less than 0.05).
Bounameaux
H
H
Holditch
T
T
Hellemans
H
H
Berent
A
A
Verhaeghe
R
R
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005121:Extremities / Q000098:blood supply; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007650:Ketanserin; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D012039:Regional Blood Flow / Q000187:drug effects; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*
D010880:Piperidines; D012702:Serotonin Antagonists; D007650:Ketanserin